352 related articles for article (PubMed ID: 34432161)
1. PARP1-modulated chromatin remodeling is a new target for cancer treatment.
Sinha S; Molla S; Kundu CN
Med Oncol; 2021 Aug; 38(10):118. PubMed ID: 34432161
[TBL] [Abstract][Full Text] [Related]
2. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Andronikou C; Rottenberg S
Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
[TBL] [Abstract][Full Text] [Related]
3. The PARP Way to Epigenetic Changes.
Ummarino S; Hausman C; Di Ruscio A
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33804735
[TBL] [Abstract][Full Text] [Related]
4. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
5. Talazoparib enhances the quinacrine-mediated apoptosis in patient-derived oral mucosa CSCs by inhibiting BER pathway through the modulation of GCN5 and P300.
Das C; Dash SR; Sinha S; Paul S; Das B; Bhal S; Sethy C; Kundu CN
Med Oncol; 2023 Nov; 40(12):351. PubMed ID: 37940725
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
7. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
8. Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions.
Zentout S; Imburchia V; Chapuis C; Duma L; Schützenhofer K; Prokhorova E; Ahel I; Smith R; Huet S
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2322689121. PubMed ID: 38865276
[TBL] [Abstract][Full Text] [Related]
9. HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs.
Valdez BC; Nieto Y; Yuan B; Murray D; Andersson BS
Oncotarget; 2022 Oct; 13():1122-1135. PubMed ID: 36243940
[TBL] [Abstract][Full Text] [Related]
10. Serine-linked PARP1 auto-modification controls PARP inhibitor response.
Prokhorova E; Zobel F; Smith R; Zentout S; Gibbs-Seymour I; Schützenhofer K; Peters A; Groslambert J; Zorzini V; Agnew T; Brognard J; Nielsen ML; Ahel D; Huet S; Suskiewicz MJ; Ahel I
Nat Commun; 2021 Jul; 12(1):4055. PubMed ID: 34210965
[TBL] [Abstract][Full Text] [Related]
11. Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly.
Molla S; Chatterjee S; Sethy C; Sinha S; Kundu CN
DNA Repair (Amst); 2021 Sep; 105():103157. PubMed ID: 34144488
[TBL] [Abstract][Full Text] [Related]
12. [Molecular mechanisms of regulaion of transcription by PARP1].
Maliuchenko NV; Kulaeva OI; Kotova E; Chupyrkina AA; Nikitin DV; Kirpichnikov MP; Studitskiĭ VM
Mol Biol (Mosk); 2015; 49(1):99-113. PubMed ID: 25916114
[TBL] [Abstract][Full Text] [Related]
13. Revisiting PARP2 and PARP1 trapping through quantitative live-cell imaging.
Zhang H; Lin X; Zha S
Biochem Soc Trans; 2022 Aug; 50(4):1169-1177. PubMed ID: 35959996
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
[TBL] [Abstract][Full Text] [Related]
15. Parp1 Deficiency Confers Defects in Chromatin Surveillance and Remodeling During Reprogramming by Nuclear Transfer.
Osada T; Nozaki T; Masutani M
Curr Protein Pept Sci; 2016; 17(7):693-704. PubMed ID: 27090907
[TBL] [Abstract][Full Text] [Related]
16. Regulation of poly(ADP-Ribose) polymerase 1 functions by post-translational modifications.
Piao L; Fujioka K; Nakakido M; Hamamoto R
Front Biosci (Landmark Ed); 2018 Jan; 23(1):13-26. PubMed ID: 28930534
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1.
Ahel D; Horejsí Z; Wiechens N; Polo SE; Garcia-Wilson E; Ahel I; Flynn H; Skehel M; West SC; Jackson SP; Owen-Hughes T; Boulton SJ
Science; 2009 Sep; 325(5945):1240-3. PubMed ID: 19661379
[TBL] [Abstract][Full Text] [Related]
18. ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification.
Rouleau-Turcotte É; Pascal JM
J Biol Chem; 2023 Dec; 299(12):105397. PubMed ID: 37898399
[TBL] [Abstract][Full Text] [Related]
19. A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase.
Kim IK; Stegeman RA; Brosey CA; Ellenberger T
J Biol Chem; 2015 Feb; 290(6):3775-83. PubMed ID: 25477519
[TBL] [Abstract][Full Text] [Related]
20. An Update on Poly(ADP-ribose) Polymerase I-A Brief Review.
Negi P; Lakshmanan K; Patel PK; Rajagopal K; Byran G
Mini Rev Med Chem; 2023; 23(18):1762-1771. PubMed ID: 36824002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
